Synthetic Biologics Inc (SYN) Up 27% After Positive Phase 2 Results are Reported

Share

Shares of Synthetic Biologics Inc (NYSEMKT:SYN) are up big today after the company announced positive Phase 2 Clinical Trial data for their Irritable Bowel Syndrome treatment, SYN-010.

The studies showed that SYN-010 was able to reduce methane production, bloating, and stomach pain, while also improving stool frequency and overall quality of life. This has caused many investors to become bullish on shares of Synthetic Biologics Inc (NYSEMKT:SYN), after this annoucement was made late yesterday, followed by a conference call this morning at 8:30 A.M. ET.

“These topline data demonstrate the positive effect of SYN-010 on decreasing gut methane production, abdominal pain and bloating, and improving stool frequency and quality of life scores in IBS-C patients who are breath-methane positive,” said Dr. Pimentel, Director of the GI Motility Program and Laboratory at Cedars-Sinai, and Chairman of Synthetic Biologics’ IBS-C Clinical Advisory Board. “Current IBS-C treatments are focused on relieving symptoms. These latest SYN-010 findings, along with previously reported topline data, strongly suggest a potential role for SYN-010 in treating a major underlying cause of IBS-C by reducing the production of methane in the gut, versus relieving symptoms.”

The stock is up 27.63% or $0.42 following the news, hitting $1.94 per share. About 4.40 million shares traded hands or up 311.21% from the average. SYN has declined 45.32% since June 15, 2015 and is currently downtrending. It has underperformed the S&P500 by 36.46%.

Synthetic Biologics, Inc. is a clinical-stage biotechnology company. The company has a market cap of $136.55 million. The Firm is developing pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome. It currently has negative earnings. It is developing an oral biologic to protect the gut microbiome microflora) from intravenous (IV) antibiotics for the prevention of C. difficile infection, an oral statin treatment to reduce the impact of methane producing organisms on irritable bowel syndrome with constipation (IBS-C) and a monoclonal antibody combination for the treatment of Pertussis.

#focuskw=’Synthetic Biologics Inc (NYSEMKT:SYN)’##metadesc=’Shares of Synthetic Biologics Inc (NYSEMKT:SYN) are up big today after the company announced positive Phase 2 Clinical Trial data for their Irritable Bowel Syndrome treatment, SYN-010.

The studies showed that SYN-010 was able to reduce methane production, bloating, and stomach pain, while also improving stool frequency and overall quality of life. This has caused many investors to become bullish on shares of Synthetic Biologics Inc (NYSEMKT:SYN), after this annoucement was made late yesterday, followed by a conference call this morning at 8:30 A.M. ET.

“These topline data demonstrate the positive effect of SYN-010 on decreasing gut methane production, abdominal pain and bloating, and improving stool frequency and quality of life scores in IBS-C patients who are breath-methane positive,” said Dr. Pimentel, Director of the GI Motility Program and Laboratory at Cedars-Sinai, and Chairman of Synthetic Biologics’ IBS-C Clinical Advisory Board. “Current IBS-C treatments are focused on relieving symptoms. These latest SYN-010 findings, along with previously reported topline data, strongly suggest a potential role for SYN-010 in treating a major underlying cause of IBS-C by reducing the production of methane in the gut, versus relieving symptoms.”

‘##metarobot=’index’##newskw=’Sony Corp (ADR) news,Sony Corp (ADR) – (NYSE:SNE),NYSE:SNE Analyst rating analysis,Stock Analysis,Outlook and potential,SNE Price change and trend,SNE stock update’##sitemap=’include’##skipsocial##stockticker=’NYSEMKT:SYN’#

COMMENTS: